(精选)ASCOT教学课件.pptVIP

ASCOT ASCOT STUDY ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES USED IN ASCOT RESULTS (BPLA published in 4/9/05) CHANGE IN GUIDELINES ?? HOW DOES IT AFFECT GP’S ?? INTRODUCTION Largest study of high blood pressure treatment ever conducted in Europe. Results were published in the European Scoiety of cardiology in September 4th 2005. Combination of effective modern antihypertensives along with lipid lowering drugs can reduce the incidence of strokes CHD, cardiovascular deaths and prevent the onset of diabetes. INTRODUCTION AND AIMS Launched in 1997 funded by Pfizer Independent investigator led study Designed to evaluate different treatment strategies for preventing cardiovascular disease in hypertensive patients. Compare the effects of two treatment strategies on non fatal MI and fatal CHD. EXISTING KNOWLEDGE Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting 800 million people worldwide. At least 80% of these would have other uncontrolled risk factors of which raised cholesterol is the commonest. We all know that reduction of blood pressure is central to reducing mortality due to MI, CVA etc. Traditionally beta blockers diuretics are used to treat hypertension Newer drugs like calcium channel blockers and ACE inhibitors are also used to treat hypertension. BACKGROUND Conducted in 650 practices and 32 regional medical centres in the UK, Ireland and the 5 Scandinavian countries.(Denmark, Norway, Sweden,Iceland and Finland) The impetus of this study was lack of outcome data on the newer types of antihypertensives. BACKGROUND contd No evidence so far on the outcome of specific combination regimes in lowering blood pressure. Evidence of shortfall in the prevention of CHD using standard therapies using beta blockers and diuretics. Need to evaluate multiple risk factor intervention in the prevention of CHD. Previous trials have shown that